TCRX

Tscan Therapeutics, Inc.

• TipRanks·06/03 14:29

  TScan Therapeutics, Cellares enter agreement to evaluate TCS-101 manufacturing

• Benzinga·06/03 13:22

  TScan Therapeutics Partners With Cellares To Evaluate Automated Clinical Manufacturing Of TSC-101, The Company's Lead TCR-T Therapy Candidate For Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes

• PUBT·06/03 13:19

  TScan Therapeutics teams with Cellares to evaluate automated manufacturing of TSC-101 TCR-T therapy

• Reuters·06/03 13:19

  TSCAN THERAPEUTICS - AGREEMENT ADDS TCR-T CELL THERAPIES TO CELLARES AUTOMATED PORTFOLIO

• TipRanks·05/22 20:49

  TScan Therapeutics Expands Authorized Shares After Stockholder Vote

• PUBT·05/22 20:07

  TScan Therapeutics shareholders approved voting common stock authorization increase to 600 million shares

• TipRanks·05/08 18:40

  Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Knight Therapeutics (OtherKHTRF) and TScan Therapeutics (TCRX)

• TipRanks·05/07 10:16

  Buy Rating Reiterated on TSC-101 Ahead of Key ALLOHA Readouts and Pipeline Expansion; $6 Price Target Maintained

• Seeking Alpha·05/07 07:19

  TScan Therapeutics GAAP EPS of -$0.22 misses by $0.01, revenue of $1M misses by $1.5M

• TipRanks·05/06 20:30

  Analysts Are Bullish on These Healthcare Stocks: Geron (GERN), Regeneron (REGN)

• TipRanks·05/06 16:37

  H.C. Wainwright Sticks to Their Buy Rating for TScan Therapeutics (TCRX)

• TipRanks·05/06 16:33

  Analysts Offer Insights on Healthcare Companies: TScan Therapeutics (TCRX), Protagonist Therapeutics (PTGX) and Disc Medicine (IRON)

• Benzinga·05/06 11:12

  TScan Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate, Sales $982.000K Miss $2.500M Estimate

• Dow Jones·05/06 11:02

  *TScan Therapeutics 2Q Loss/Shr 22c >TCRX

• Dow Jones·05/06 11:02

  *TScan Therapeutics 2Q Loss $28.7M >TCRX